Severity of haemolytic disease of the fetus and newborn in patients with a history of intrauterine transfusions in a previous pregnancy: A nationwide retrospective cohort study
- PMID: 37743689
- DOI: 10.1111/1471-0528.17674
Severity of haemolytic disease of the fetus and newborn in patients with a history of intrauterine transfusions in a previous pregnancy: A nationwide retrospective cohort study
Abstract
Objective: Pregnant women who received at least one intrauterine transfusion (IUT) for haemolytic disease of the fetus and newborn (HDFN) in the preceding pregnancy are presumed to have a high likelihood of requiring IUTs again, often starting at an earlier gestational age. Our aim was to quantify these risks in a large national cohort.
Design: Retrospective cohort study of a nationwide Dutch database.
Setting: The Netherlands.
Population: All women treated in The Netherlands with IUTs for Rhesus D (RhD)- or Kell-mediated HDFN between 1999 and 2017 and their follow-up pregnancies were included. Pregnancies with an antigen-negative fetus were excluded.
Methods: Electronic patient files were searched for the number and gestational age of each IUT, and analysed using descriptive statistics and linear regression.
Main outcome measures: Percentage of women requiring one or more IUTs again in the subsequent pregnancy, and gestational age at first IUT in both pregnancies.
Results: Of the 321 women in our study population, 21% (69) had a subsequent ongoing pregnancy at risk. IUTs were administered in 86% (59/69) of cases. In subsequent pregnancies, the median gestational age at first IUT was 3 weeks earlier (interquartile range -6.8 to 0.4) than in the preceding pregnancy.
Conclusions: Our study shows that pregnant women with a history of IUTs in the previous pregnancy are highly likely to require IUTs again, and on average 3 weeks earlier. Clinicians need to be aware of these risks and ensure timely referral, and close surveillance from early pregnancy onwards. Additionally, for women with a history of IUT and their caregivers, this information is essential to enable adequate preconception counselling.
Keywords: alloimmunisation; fetal anaemia; fetal therapy; haemolytic disease of the fetus and newborn.
© 2023 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Castleman JS, Kilby MD. Red cell alloimmunisation: A 2020 update. Prenat Diagn. 2020;10:1002.
-
- Zwiers C, Van der Bom JG, Van Kamp IL, Van Geloven N, Lopriore E, Smoleniec J, et al. Postponing early intrauterine transfusion with intravenous immunoglobulin treatment; The PETIT study on severe haemolytic disease of the fetus and newborn. Am J Obstet Gynecol. 2018;219(3):291.e1–291.e9.
-
- Zwiers C, Oepkes D, Lopriore E, Klumper FJ, de Haas M, van Kamp IL. The near disappearance of fetal hydrops in relation to current state‐of‐the‐art management of red cell alloimmunization. Prenat Diagn. 2018;38(12):943–950.
-
- Koelewijn JM, de Haas M, Vrijkotte TG, van der Schoot CE, Bonsel GJ. Risk factors for RhD immunisation despite antenatal and postnatal anti‐D prophylaxis. BJOG. 2009;116(10):1307–1314.
-
- Scheffer PG, van der Schoot C, Page‐Christiaens GC, de Haas M. Noninvasive fetal blood group genotyping of rhesus D, C, E and K in alloimmunised pregnant women: evaluation of a 7‐year clinical experience. BJOG. 2011;118:1340–1348.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical